JP2019533684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533684A5 JP2019533684A5 JP2019522381A JP2019522381A JP2019533684A5 JP 2019533684 A5 JP2019533684 A5 JP 2019533684A5 JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019533684 A5 JP2019533684 A5 JP 2019533684A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- combination
- leucovorin
- irinotecan
- oxaliplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004768 irinotecan Drugs 0.000 claims description 62
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 62
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 46
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 46
- 235000008191 folinic acid Nutrition 0.000 claims description 46
- 239000011672 folinic acid Substances 0.000 claims description 46
- 229960001691 leucovorin Drugs 0.000 claims description 46
- 239000002502 liposome Substances 0.000 claims description 44
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 38
- 229960002949 fluorouracil Drugs 0.000 claims description 38
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 38
- 229960001756 oxaliplatin Drugs 0.000 claims description 38
- 238000002560 therapeutic procedure Methods 0.000 claims description 35
- 230000000259 anti-tumor effect Effects 0.000 claims description 34
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
- 206010017758 gastric cancer Diseases 0.000 claims description 22
- 201000011549 stomach cancer Diseases 0.000 claims description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000003457 anti-vomiting effect Effects 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000002895 emetic Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims 1
- RZBMBMLIIRIAMH-LDLOPFEMSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(octadecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCCCC)=O RZBMBMLIIRIAMH-LDLOPFEMSA-N 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 229960005277 gemcitabine Drugs 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022146925A JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416317P | 2016-11-02 | 2016-11-02 | |
| US62/416,317 | 2016-11-02 | ||
| PCT/GB2017/053293 WO2018083470A1 (en) | 2016-11-02 | 2017-11-01 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146925A Division JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533684A JP2019533684A (ja) | 2019-11-21 |
| JP2019533684A5 true JP2019533684A5 (cg-RX-API-DMAC7.html) | 2020-12-10 |
Family
ID=60569939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522381A Ceased JP2019533684A (ja) | 2016-11-02 | 2017-11-01 | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
| JP2022146925A Pending JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146925A Pending JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Country Status (18)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4218730B1 (en) * | 2004-05-03 | 2023-11-01 | Ipsen Biopharm Ltd. | Liposomes useful for drug delivery |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US20170049775A1 (en) | 2015-08-21 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin |
| CN114099437A (zh) | 2015-10-16 | 2022-03-01 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
| JP6728482B2 (ja) | 2017-03-31 | 2020-07-22 | 富士フイルム株式会社 | リポソーム組成物および医薬組成物 |
| PL3811931T3 (pl) | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| CN112789032A (zh) * | 2018-10-01 | 2021-05-11 | 富士胶片株式会社 | 包含内含药物的脂质体组合物及铂制剂的组合医药 |
| CN113164600A (zh) * | 2018-10-17 | 2021-07-23 | 百欧林纳克斯有限公司 | 转移性胰脏腺癌的治疗 |
| US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| EP3988086A1 (en) * | 2019-02-22 | 2022-04-27 | Novocure GmbH | Treating gastric cancer using ttfields and drug in combination |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| AU4990397A (en) | 1996-10-22 | 1998-05-15 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US6355268B1 (en) | 1998-09-16 | 2002-03-12 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US7025988B2 (en) | 2000-02-04 | 2006-04-11 | Lipoxen Technologies Limited | Liposomes |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| AU2001261473B2 (en) | 2000-05-15 | 2006-09-14 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for the treatment of colorectal cancer |
| MXPA02012817A (es) | 2000-06-30 | 2004-07-30 | Inex Pharmaceuticals Inc | Drogas antineoplasicas liposomales y uso de las mismas. |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| AU2002305094B2 (en) | 2001-03-26 | 2007-01-11 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| JP2005505526A (ja) | 2001-07-23 | 2005-02-24 | エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト | Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法 |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2752143C (en) | 2002-05-15 | 2014-09-23 | Sutter West Bay Hospitals | Delivery of nucleic acid-like compounds |
| ATE458751T1 (de) | 2002-05-31 | 2010-03-15 | Transmolecular Inc | Kombinationschemotherapie mit chlorotoxin |
| AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| EP4218730B1 (en) | 2004-05-03 | 2023-11-01 | Ipsen Biopharm Ltd. | Liposomes useful for drug delivery |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| US7846473B2 (en) * | 2004-06-01 | 2010-12-07 | Terumo Kabushiki Kaisha | Irinotecan preparation |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| AU2006306108B2 (en) | 2005-10-25 | 2012-10-04 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| US20090148506A1 (en) | 2005-12-22 | 2009-06-11 | Awa Dicko | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| DK2338487T3 (da) | 2006-01-17 | 2013-12-09 | Abbvie Bahamas Ltd | Kombinationsterapi med PARP-inhibitorer |
| CN101442998B (zh) | 2006-03-16 | 2012-03-14 | 比奥纽默里克药物公司 | 抗癌活性加强化合物和制剂及其用法 |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| US20100239652A1 (en) | 2007-09-28 | 2010-09-23 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| CA2705417A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| EP2224804A4 (en) | 2007-12-07 | 2011-06-01 | Bipar Sciences Inc | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS |
| EP2259797A2 (en) | 2008-03-25 | 2010-12-15 | Schering Corporation | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| EP2860260A1 (en) | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| EP2424516A4 (en) | 2009-05-01 | 2014-04-02 | Oncozyme Pharma Inc | PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER |
| KR20120089754A (ko) | 2009-12-03 | 2012-08-13 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법 |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| JP2013531068A (ja) | 2010-07-19 | 2013-08-01 | バイパー サイエンシズ，インコーポレイティド | ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法 |
| MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
| RU2541100C2 (ru) | 2010-09-03 | 2015-02-10 | Боард Оф Регентс Оф Зе Юниверсити Оф Небраска | Способ и композиция для лечения рака |
| JP6208582B2 (ja) | 2010-12-06 | 2017-10-04 | メリマック ファーマシューティカルズ インコーポレーティッド | アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与 |
| WO2012079582A1 (en) | 2010-12-14 | 2012-06-21 | Technical University Of Denmark | Entrapment of radionuclides in nanoparticle compositions |
| AU2012217685B2 (en) | 2011-02-15 | 2017-05-18 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| HRP20170713T1 (hr) | 2011-04-19 | 2017-07-14 | Merrimack Pharmaceuticals, Inc. | Bispecifično anti-igf-1r i anti-erbb3 antitijelo |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| KR20150050524A (ko) | 2012-04-17 | 2015-05-08 | 메리맥 파마슈티컬즈, 인크. | 비침습적 이미징을 위한 조성물 및 방법 |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014113167A1 (en) | 2012-12-14 | 2014-07-24 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| HUE041687T2 (hu) | 2013-03-27 | 2019-05-28 | Taiho Pharmaceutical Co Ltd | Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot |
| EP3038600B1 (en) | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| WO2016094402A1 (en) | 2014-12-09 | 2016-06-16 | Merrimack Pharmaceuticals, Inc. | Treatment of breast cancer with liposomal irinotecan |
| TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US20170049775A1 (en) | 2015-08-21 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin |
| CN114099437A (zh) | 2015-10-16 | 2022-03-01 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| CN109640995A (zh) | 2016-05-18 | 2019-04-16 | 易普森生物制药有限公司 | 用脂质体伊立替康治疗小细胞肺癌 |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
-
2017
- 2017-11-01 RU RU2019114952A patent/RU2761953C2/ru active
- 2017-11-01 MY MYPI2019002087A patent/MY202377A/en unknown
- 2017-11-01 MA MA046709A patent/MA46709A/fr unknown
- 2017-11-01 CA CA3040395A patent/CA3040395A1/en active Pending
- 2017-11-01 SG SG11201903615WA patent/SG11201903615WA/en unknown
- 2017-11-01 SG SG10201912338RA patent/SG10201912338RA/en unknown
- 2017-11-01 CN CN201780080584.XA patent/CN110402163A/zh active Pending
- 2017-11-01 AU AU2017354903A patent/AU2017354903B2/en active Active
- 2017-11-01 WO PCT/GB2017/053293 patent/WO2018083470A1/en not_active Ceased
- 2017-11-01 BR BR112019007844A patent/BR112019007844A2/pt not_active IP Right Cessation
- 2017-11-01 EA EA201990979A patent/EA201990979A1/ru unknown
- 2017-11-01 US US16/346,436 patent/US11071726B2/en not_active Expired - Fee Related
- 2017-11-01 TW TW106137766A patent/TWI791467B/zh active
- 2017-11-01 JP JP2019522381A patent/JP2019533684A/ja not_active Ceased
- 2017-11-01 KR KR1020197014970A patent/KR20190077441A/ko not_active Ceased
- 2017-11-01 MX MX2019004783A patent/MX392408B/es unknown
- 2017-11-01 EP EP17808557.7A patent/EP3535026A1/en not_active Ceased
-
2019
- 2019-04-23 IL IL266187A patent/IL266187A/en unknown
- 2019-04-24 PH PH12019500892A patent/PH12019500892A1/en unknown
-
2022
- 2022-03-24 IL IL291679A patent/IL291679A/en unknown
- 2022-09-15 JP JP2022146925A patent/JP2022171808A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533684A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528185A5 (cg-RX-API-DMAC7.html) | ||
| He et al. | Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment | |
| RU2019114952A (ru) | Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин | |
| JP2015523355A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528184A5 (cg-RX-API-DMAC7.html) | ||
| JP5890780B2 (ja) | 中枢を介する悪心および嘔吐を治療するための組成物および方法 | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| RU2018105666A (ru) | Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина | |
| JP2014088444A5 (cg-RX-API-DMAC7.html) | ||
| JP2019504100A5 (cg-RX-API-DMAC7.html) | ||
| FI3821887T3 (fi) | Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon | |
| JP2017081920A (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| JP7015237B2 (ja) | 腫瘍の成長を抑制する方法 | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2021509395A5 (cg-RX-API-DMAC7.html) | ||
| JP2008540364A5 (cg-RX-API-DMAC7.html) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| DE60025494T2 (de) | Epothilon zusammensetzungen | |
| JP2008517991A5 (cg-RX-API-DMAC7.html) | ||
| WO2015191576A1 (en) | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy | |
| WO2001083020A1 (en) | Antineoplastic platinum therapeutic method and composition | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| JP2019525924A5 (cg-RX-API-DMAC7.html) | ||
| Litvinova et al. | Features of the Patent Researches of Nanotechnology-Based Drug Development. |